Clinical Trials Directory

Trials / Completed

CompletedNCT01019057

An Evaluation of Interlaminar Lumbar Instrumented (ILIF™)

A Prospective, Non-randomized, Multi-Center Evaluation of Interlaminar Lumbar Instrumented (ILIF™)

Status
Completed
Phase
Study type
Observational
Enrollment
77 (actual)
Sponsor
NuVasive · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

Patients diagnosed with single-level degenerative disc disease (DDD) of the lumbar spine undergo a posterior decompression followed by a fusion complete with a spinous process plate, graft, and a biologic.

Detailed description

Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion. Because this compound solution requires only a midline incision rather than the far lateral exposure necessary in posterolateral fusion with pedicle screws, it is less invasive to the patient, and therefore should result in less postoperative pain and disability, broadening the applicability of the procedure to even those advanced in age or with existing comorbidities. Subjects will be followed for 24 months following surgery to determine the changes in ODI scores from preoperative to baseline assessments. This data will be compared to published data on similar procedures.

Conditions

Interventions

TypeNameDescription
PROCEDUREILIFInterlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.

Timeline

Start date
2009-11-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2009-11-25
Last updated
2025-12-24

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01019057. Inclusion in this directory is not an endorsement.